CN103239486B - 治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 - Google Patents
治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 Download PDFInfo
- Publication number
- CN103239486B CN103239486B CN201310172784.1A CN201310172784A CN103239486B CN 103239486 B CN103239486 B CN 103239486B CN 201310172784 A CN201310172784 A CN 201310172784A CN 103239486 B CN103239486 B CN 103239486B
- Authority
- CN
- China
- Prior art keywords
- solution
- ginkgolides
- need testing
- ethanol
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 6
- 241000218628 Ginkgo Species 0.000 title abstract description 23
- 235000011201 Ginkgo Nutrition 0.000 title abstract description 23
- 235000008100 Ginkgo biloba Nutrition 0.000 title abstract description 23
- 150000002596 lactones Chemical class 0.000 title abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 318
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 143
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 43
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000011347 resin Substances 0.000 claims abstract description 20
- 229920005989 resin Polymers 0.000 claims abstract description 20
- 238000000926 separation method Methods 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims description 164
- 238000012360 testing method Methods 0.000 claims description 135
- 229930184727 ginkgolide Natural products 0.000 claims description 105
- 239000013558 reference substance Substances 0.000 claims description 60
- 239000000706 filtrate Substances 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 39
- 238000010992 reflux Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 9
- 238000010792 warming Methods 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 238000010812 external standard method Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 2
- 238000010813 internal standard method Methods 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 abstract description 136
- 238000000605 extraction Methods 0.000 abstract description 47
- 241000196324 Embryophyta Species 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 239000013078 crystal Substances 0.000 description 58
- 238000010828 elution Methods 0.000 description 43
- 239000000284 extract Substances 0.000 description 39
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- 238000003756 stirring Methods 0.000 description 30
- 239000002904 solvent Substances 0.000 description 26
- 239000007924 injection Substances 0.000 description 24
- 238000002347 injection Methods 0.000 description 24
- 239000003480 eluent Substances 0.000 description 21
- 238000010438 heat treatment Methods 0.000 description 20
- -1 terpene lactone Chemical class 0.000 description 20
- 239000012071 phase Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 230000008025 crystallization Effects 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 13
- 229920002521 macromolecule Polymers 0.000 description 13
- 238000007689 inspection Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000004952 Polyamide Substances 0.000 description 11
- 235000015165 citric acid Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 150000002605 large molecules Chemical class 0.000 description 11
- 229920002647 polyamide Polymers 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- 238000009835 boiling Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 9
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 9
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 9
- 229930182817 methionine Natural products 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 8
- 238000000105 evaporative light scattering detection Methods 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 7
- 108010003541 Platelet Activating Factor Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000005057 refrigeration Methods 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 6
- 239000012088 reference solution Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000007586 terpenes Nutrition 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 244000194101 Ginkgo biloba Species 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 239000012490 blank solution Substances 0.000 description 5
- 239000012159 carrier gas Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 150000003891 oxalate salts Chemical class 0.000 description 5
- 229910001414 potassium ion Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000008354 sodium chloride injection Substances 0.000 description 5
- 235000018553 tannin Nutrition 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020843 Hyperthermia Diseases 0.000 description 3
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 3
- 238000002270 exclusion chromatography Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 229920006122 polyamide resin Polymers 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 229930009674 sesquiterpene lactone Natural products 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940123251 Platelet activating factor antagonist Drugs 0.000 description 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000703 anti-shock Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000030769 platelet activating factor receptor Human genes 0.000 description 2
- 238000011046 pyrogen test Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 244000294925 Tragopogon dubius Species 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- GMGLYSIINJPYLI-UHFFFAOYSA-N butan-2-one;propan-2-one Chemical compound CC(C)=O.CCC(C)=O GMGLYSIINJPYLI-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
考察项目 | 方法一 | 方法二 |
外观性状 | 棕色粉末 | 棕色粉末 |
总内酯含量(%) | 14.1 | 10.8 |
考察项目 | 方法一 | 方法二 | 方法三 |
外观性状 | 黄色粉末 | 黄色粉末 | 黄色粉末 |
总内酯含量(%) | 47.8 | 35.5 | 38.2 |
溶剂加入量(倍) | 4 | 6 | 8 | 10 |
加热溶解情况 | 未溶完 | 溶解完全 | 溶解完全 | 溶解完全 |
晶体量(g) | 3.8 | 4.5 | 4.2 | 2.4 |
溶剂加入量(倍) | 4 | 6 | 8 | 10 |
加热溶解情况 | 溶解完全 | 溶解完全 | 溶解完全 | 溶解完全 |
晶体量(g) | 2.3 | 3.5 | 3.8 | 3.2 |
溶剂加入量(倍) | 4 | 6 | 8 | 10 |
加热溶解情况 | 未溶完 | 溶解完全 | 溶解完全 | 溶解完全 |
晶体量(g) | 2.3 | 3.5 | 3.3 | 2.2 |
银杏内酯 | 银杏内酯A | 银杏内酯B | 银杏内酯C | 白果内酯 | 银杏内酯J |
分子式 | C20H24O9 | C20H24O10 | C20H24O11 | C15H18O8 | C20H24O10 |
分子量 | 408.4 | 424.4 | 440.4 | 326.3 | 424.4 |
[M+Na]+ | M |
419.1、431.5、447.4、463.3、475.7、532.2、588.8、701.8 | 396.1、408.5、424.4、440.3、452.7、509.2、678.8 |
编号 | 1# | 2# | 3# | 4# | 5# | 6# |
总银杏酸检查结果 | 未检出 | 未检出 | 未检出 | 未检出 | 未检出 | 未检出 |
批号 | 100401 | 100402 | 100403 | 100404 | 110101 |
相似度 | 0.992 | 0.997 | 0.991 | 0.996 | 0.982 |
批号 | 110102 | 110103 | 110601 | 110602 | 110603 |
相似度 | 0.999 | 0.997 | 0.992 | 0.993 | 0.989 |
试管编号 | 1 | 2 | 3 | 4 | 5 |
2%红细胞悬液/ml | 2.5 | 2.5 | 2.5 | 2.5 | |
0.9%氯化钠溶液/ml | 2.2 | 2.2 | 2.5 | 4.7 | |
蒸馏水/ml | 2.5 | ||||
供试品溶液/ml | 0.3 | 0.3 | 0.3 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310172784.1A CN103239486B (zh) | 2012-04-23 | 2012-04-23 | 治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310172784.1A CN103239486B (zh) | 2012-04-23 | 2012-04-23 | 治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210121252.0A Division CN102659808B (zh) | 2012-04-23 | 2012-04-23 | 一种银杏内酯的提取分离方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103239486A CN103239486A (zh) | 2013-08-14 |
CN103239486B true CN103239486B (zh) | 2014-09-10 |
Family
ID=48919591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310172784.1A Active CN103239486B (zh) | 2012-04-23 | 2012-04-23 | 治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103239486B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115015435B (zh) * | 2022-06-30 | 2024-03-22 | 山东新华医疗器械股份有限公司 | 一种消毒剂中n-乙酰基己内酰胺的检测方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1267726C (zh) * | 2003-08-22 | 2006-08-02 | 北京大学 | 一种有机残留物的检测方法 |
CN100367031C (zh) * | 2004-12-07 | 2008-02-06 | 中国中医科学院中药研究所 | 大孔吸附树脂固体顶空进样有机残留物检测方法 |
CN1322870C (zh) * | 2005-10-21 | 2007-06-27 | 云南白药集团股份有限公司 | 虎尾草黄酮胶囊的质量控制方法 |
CN101858893A (zh) * | 2009-04-07 | 2010-10-13 | 北京协和药厂 | 大孔树脂提取物中残留溶剂的顶空气相色谱检测方法 |
CN102343021B (zh) * | 2010-08-02 | 2014-12-10 | 天津丹溪国药研究所 | 一种制备桂附地黄胶囊的工艺方法 |
CN102343020B (zh) * | 2010-08-02 | 2014-12-10 | 天津丹溪国药研究所 | 一种制备桂附地黄滴丸的工艺方法 |
CN102288697B (zh) * | 2011-07-07 | 2013-05-08 | 浙江中一检测研究院股份有限公司 | 一种空气和废气中己内酰胺含量的测定方法 |
-
2012
- 2012-04-23 CN CN201310172784.1A patent/CN103239486B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103239486A (zh) | 2013-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102659808B (zh) | 一种银杏内酯的提取分离方法 | |
CN101721567B (zh) | 一种石菖蒲提取物及其制备方法和应用 | |
CN100418512C (zh) | 生脉输液的制备方法 | |
CN103239487B (zh) | 银杏内酯注射液及含量测定方法 | |
CN102488819B (zh) | 萱草花提取物的制备方法 | |
CN101322748B (zh) | 一种贯叶连翘总黄酮及其制剂的制备方法和质量检测方法 | |
CN100400055C (zh) | 一种伏生紫堇总碱及其制备方法和其药物组合物 | |
CN103091412B (zh) | 一种银杏内酯有效部位检测方法 | |
CN103163252B (zh) | 银杏内酯组合物中总银杏酸的测定方法 | |
CN101745035A (zh) | 治疗中风的胶囊制剂的质量控制方法 | |
CN103239486B (zh) | 治疗心脑血管疾病的银杏内酯组合物中残留物的测定方法 | |
CN103202839B (zh) | 治疗心脑血管疾病的银杏内酯组合物 | |
CN100522191C (zh) | 一种丹参药材指纹图谱检测方法 | |
CN102670670B (zh) | 一种高银杏萜类内酯含量的银杏达莫注射液的制备方法 | |
CN102091114A (zh) | 一种中药冻干注射剂及其制备方法 | |
CN100444849C (zh) | 刺蒺藜提取物的新用途 | |
CN109632990B (zh) | 一种同时测定板蓝根制剂中直铁线莲宁b和(r,s)-告衣春含量的方法 | |
CN106420851B (zh) | 一种舒血宁注射液及其制备方法 | |
CN106420850B (zh) | 银杏叶组合物及其在制备舒血宁注射液中的应用 | |
CN101612184A (zh) | 多舌飞蓬提取物、含该提取物的组合物及制备方法和用途 | |
CN102626383A (zh) | 银杏内酯注射液及其制备方法 | |
CN111686138B (zh) | 一种绿萍提取物及其制备方法和其应用 | |
CN1660184B (zh) | 一种含有肿节风提取物的药物组合物及其制备方法和用途 | |
CN107915742A (zh) | 一种银杏二萜内酯的提取分离方法 | |
CN1772008B (zh) | 注射用银杏达莫的制备方法及质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611130, Chengdu District, Sichuan, Wenjiang province Chengdu science and Technology Industrial Development Park on both sides of the Taiwan Straits, No. 433 west section of Willow Road Patentee after: CHENGDU BAIYU PHARMACEUTICAL CO., LTD. Address before: 611130, Chengdu District, Sichuan, Wenjiang province Chengdu science and Technology Industrial Development Park on both sides of the Taiwan Straits, No. 433 west section of Willow Road Patentee before: Chengdu Baiyu Technology Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Residue determination method of ginkgo lactone composition for treating cardiovascular and cerebrovascular diseases Effective date of registration: 20160614 Granted publication date: 20140910 Pledgee: Bank of Guiyang, Limited by Share Ltd, Chengdu branch Pledgor: CHENGDU BAIYU PHARMACEUTICAL CO., LTD. Registration number: 2016510000018 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190429 Granted publication date: 20140910 Pledgee: Bank of Guiyang, Limited by Share Ltd, Chengdu branch Pledgor: CHENGDU BAIYU PHARMACEUTICAL CO., LTD. Registration number: 2016510000018 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Determination of residues in ginkgolide composition for treating cardiovascular and cerebrovascular diseases Effective date of registration: 20220316 Granted publication date: 20140910 Pledgee: Bank of Guiyang Limited by Share Ltd. Chengdu branch Pledgor: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980002594 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |